# US 2024/0002853 A1 · Nucleic acid duplexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002853 A1
- Document ID: US20240002853A1
- Status: Published application
- Kind: A1
- Application number: 18/253,853
- Filed: 2021-11-22
- Published: 2024-01-04
- Earliest claimed: 2020-11-23
- Assignees: Alpha Anomeric SAS
- Applicants: Alpha Anomeric SAS
- Inventors: Wolfgang RENNER; Damien EVÉQUOZ
- Web page: https://patentgrep.com/patent/US20240002853A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/32: of the sugar
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/52: modulating the physical stability, e.g. GC-content
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound comprising a first oligomeric compound and a second oligomeric compound, wherein the first oligomeric compound comprises a first oligonucleotide and said second oligomeric compound comprises a second oligonucleotide, wherein said first oligonucleotide has a nucleobase sequence that is complementary to a nucleic acid target, and wherein preferably said first oligonucleotide is an antisense oligonucleotide; and wherein said second oligonucleotide has a nucleobase sequence that is complementary to the nucleobase sequence of the first oligonucleotide; and wherein the affinity of said first oligonucleotide to said second oligonucleotide is lower than the affinity of said first oligonucleotide to the fully complementary unmodified RNA oligonucleotide of said first oligonucleotide; or wherein the biostability of said second oligonucleotide is lower than the biostability of said first oligonucleotide.

## Claims

### Claim 1

A compound comprising a first oligomeric compound and a second oligomeric compound, wherein the first oligomeric compound comprises a first oligonucleotide and said second oligomeric compound comprises a second oligonucleotide, wherein
said first oligonucleotide comprises at least one abc-DNA nucleoside, wherein said first oligonucleotide has a nucleobase sequence that is complementary to a nucleic acid target, and wherein preferably said first oligonucleotide is an antisense oligonucleotide; and wherein
said second oligonucleotide has a nucleobase sequence that is complementary to the nucleobase sequence of the first oligonucleotide.

### Claim 2 (depends on 1)

The compound of claim 1, wherein at least 50% of the nucleosides of the first oligonucleotide are abc-DNA nucleosides.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or claim 2, wherein said first oligonucleotide comprises at least 8 and at most 50 nucleotides.

### Claim 4

The compound of any one of the preceding claims, wherein at most five, preferably at most four, further preferably at most three, more preferably at most two, and yet more preferably only one of all internucleoside linkages of said first oligonucleotide are phosphorothioate internucleoside linkages, and the remaining internucleoside linkages of said first oligonucleotide are phosphodiester linkages.

### Claim 5

The compound of any one of the preceding claims, wherein all internucleoside linkages of said first oligonucleotide are phosphodiester linkages.

### Claim 6

The compound of any one of the preceding claims, wherein at least 70% of the sugar moieties of said second oligonucleotide are unmodified DNA sugar moieties, preferably wherein at least 80%, more preferably at least 90%, more preferably at least 95%, and yet more preferably 100% of the sugar moieties of said second oligonucleotide are unmodified DNA sugar moieties, and wherein preferably at most three of all internucleoside linkages of said second oligonucleotide are phosphorothioate internucleoside linkages, wherein preferably said phosphorothioate internucleoside linkages are positioned at the 5′-end and/or at the 3′-end of said second oligonucleotide.

### Claim 7

The compound of any one of the preceding claims, wherein each sugar moiety of said second oligonucleotide is an unmodified DNA sugar moiety, wherein at most four of all internucleoside linkages of said second oligonucleotide are phosphorothioate internucleoside linkages, wherein preferably said phosphorothioate internucleoside linkages are positioned at the 5′-end and/or at the 3′-end of said second oligonucleotide.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of the claims 1 to 6, wherein said second oligonucleotide comprises at least one modified sugar moiety selected from the group consisting of (i) a non-bicyclic modified sugar moiety comprising a furanosyl ring with one or more acyclic substituent at the 2′, 4′, and/or 5′ position, (ii) a bicyclic sugar moiety, and (iii) a sugar surrogate.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 8)

The compound of any one of the claims 1 to 6 and 8, wherein said second oligonucleotide consists of modified nucleosides selected from the group consisting of (i) a non-bicyclic modified sugar moiety comprising a furanosyl ring with one or more acyclic substituent at the 2′, 4′, and/or 5′ position, (ii) a bicyclic sugar moiety, (iii) a sugar surrogate.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 8, 9)

The compound of any one of the claims 1 to 6 and 8 to 9, wherein said second oligonucleotide consists of modified nucleosides, wherein said modified nucleosides are selected from the group consisting of a 2′-MOE nucleoside, 2′-OMe nucleoside, an abc-DNA nucleoside, a FANA, and a morpholino.

### Claim 11 (depends on 1, 2, 3)

The compound of any one of the claims 1 to 3, wherein said first oligonucleotide is a gapmer comprising a gap, a 5′ wing and a 3′ wing.

### Claim 12 (depends on 11)

The compound of claim 11, wherein said gap of said gapmer comprises unmodified DNA sugar moieties.

### Claim 13 (depends on 11, 12)

The compound of any one of the claims 11 to 12, wherein said 5′ wing of said gapmer comprises at least one abc-DNA nucleoside; and/or wherein said 3′ wing of said gapmer comprises at least one abc-DNA nucleoside.

### Claim 14 (depends on 11, 12, 13)

The compound of any one of the claims 11 to 13, wherein said 5′ wing of said gapmer comprises at least one abc-DNA nucleoside, preferably wherein said 5′ wing of said gapmer comprises at least two abc-DNA nucleosides, preferably at least three abc-DNA nucleosides, yet more preferably at least four abc-DNA nucleosides, and again more preferably at least five abc-DNA nucleosides; preferably wherein said abc-DNA nucleosides are contiguous.

### Claim 15 (depends on 11, 12, 13, 14)

The compound of any one of the claims 11 to 14, wherein said 3′ wing of said gapmer comprises at least one abc-DNA nucleoside, preferably wherein said 3′ wing of said gapmer comprises at least two abc-DNA nucleosides, preferably at least three abc-DNA nucleosides, yet more preferably at least four abc-DNA nucleosides, and again more preferably at least five abc-DNA nucleosides; preferably wherein said abc-DNA nucleosides are contiguous.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The compound of any one of the claims 11 to 15, wherein said 5′ wing of said gapmer comprises at least four abc-DNA nucleosides, and wherein said 3′ wing of said gapmer comprises at least four abc-DNA nucleosides.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The compound of any one of the claims 11 to 16, wherein said gap comprises at least five unmodified DNA sugar moieties, preferably at least six unmodified DNA sugar moieties, preferably at least seven unmodified DNA sugar moieties, preferably at least eight unmodified DNA sugar moieties, yet preferably at least nine unmodified DNA nucleosides, yet more preferably at least ten unmodified DNA sugar moieties.

### Claim 18 (depends on 11, 12, 13, 14, 15, 16, 17)

The compound of any one of the claims 11 to 17, wherein said gap of said gapmer consists of unmodified DNA sugar moieties; said 5′ wing of said gapmer consists of abc-DNA nucleosides; and said 3′ wing of said gapmer consists of abc-DNA nucleosides.

### Claim 19 (depends on 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of the claims 11 to 18, wherein at least 20% of the internucleoside linkages within said gap of said gapmer are phosphodiester internucleoside linkages.

### Claim 20 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of the claims 11 to 19, wherein at least 50% of the internucleoside linkages within said gap of said gapmer are phosphodiester internucleoside linkages.

### Claim 21 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The compound of any of the claims 11 to 20, wherein all of the internucleoside linkages within said gap of said gapmer are phosphodiester internucleoside linkages.

### Claim 22 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any of the claims 11 to 21, wherein at least 70% of the internucleoside linkages within said 5′ wing of said gapmer are phosphodiester internucleoside linkages.

### Claim 23 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any of the claims 11 to 22, wherein at least 70% of the internucleoside linkages within said 3′ wing of said gapmer are phosphodiester internucleoside linkages.

### Claim 24 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound of any one of the claims 11 to 23, wherein 100% of the internucleoside linkages within said 5′ wing and/or said 3′ wing of said gapmer are phosphodiester internucleoside linkages.

### Claim 25 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any of claims 11 to 24, wherein the internucleoside linkage between said 5′ wing and said gap of said gapmer is a phosphodiester internucleoside linkage.

### Claim 26 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any of claims 11 to 25, wherein the internucleoside linkage between said 3′ wing and said gap of said gapmer a phosphodiester internucleoside linkage.

### Claim 27 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 11 to 26, wherein said second oligonucleotide comprises at least one unmodified nucleoside.

### Claim 28 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound any one of claims 11 to 27, wherein at least one unmodified nucleoside is an unmodified RNA nucleoside.

### Claim 29 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 11 to 28, wherein said second oligonucleotide consists of unmodified RNA nucleosides.

### Claim 30 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 11 to 28, wherein said second oligonucleotide further comprises at least one modified nucleoside, preferably wherein said at least one modified nucleoside is an abcDNA nucleoside or an MOE nucleoside.

### Claim 31 (depends on 30)

The compound of claim 30, wherein said at least one modified nucleoside is positioned at the 5′ end and/or the 3′ end of said second oligonucleotide.

### Claim 32 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31)

The compound of any one of claims 11 to 28 or 30 to 31, wherein said second oligonucleotide comprises at most four, preferably at most three, more preferably at most two, more preferably one modified nucleoside and wherein said modified nucleoside is 5′ end and/or the 3′ end of said second oligonucleotide.

### Claim 33 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 11 to 32, wherein at least 80% of the internucleoside linkages within said second oligonucleotide are phosphodiester linkages, preferably wherein at least 90% of the internucleoside linkages with said second oligonucleotide are phosphodiester linkages, more preferably wherein all of the internucleoside linkages within said second oligonucleotide are phosphodiester linkages.

### Claim 34 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33)

The compound of claims 11 to 28 and 30 to 33, wherein at least 70% of the sugar moieties of said second oligonucleotide are unmodified RNA sugar moieties, preferably wherein at least 80%, more preferably at least 90%, more preferably at least 95%, and yet more preferably 100% of the sugar moieties of said second oligonucleotide are unmodified RNA sugar moieties, and wherein preferably at most three of all internucleoside linkages of said second oligonucleotide are phosphorothioate internucleoside linkages, wherein preferably said phosphorothioate internucleoside linkages are positioned at the 5′ end and/or at the 3′ end of said second oligonucleotide.

### Claim 35 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34)

The compound of any one of claims 11 to 29 and 33 to 34, wherein each sugar moiety of said second oligonucleotide is an unmodified RNA sugar moiety, wherein at most three of all internucleoside linkages of said second oligonucleotide are phosphorothioate internucleoside linkages, wherein preferably said phosphorothioate internucleoside linkages are positioned at the 5′-end and/or at the 3′-end of said second oligonucleotide.

### Claim 36 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 35)

The compound of any one of the claims 11 to 29 and 33 to 35, wherein each sugar moiety of said second oligonucleotide is an unmodified RNA sugar moiety, and wherein each internucleoside linkage of said second oligonucleotide is a phosphodiester linkage.

### Claim 37 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The compound of any one of claims 11 to 36, wherein said 5′ wing of said gapmer comprises at most five unpaired overhanging nucleotides.

### Claim 38 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound of any one of claims 11 to 37, wherein said 3′ wing of said gapmer comprises at most five unpaired overhanging nucleotides.

### Claim 39

A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable carrier.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any of the claims 1 to 38 or the pharmaceutical composition of claim 39, for use in the prevention or treatment of a disease, wherein preferably said disease is a neuromuscular or musculoskeletal disease, and wherein further preferably the neuromuscular or musculoskeletal disease is selected from the group consisting of Duchenne muscular dystrophy, familial dysautonomia, spinal muscular atrophy, ataxia telangiectasia, congenital disorder of glycosylation, fronto-temporal dementia, Parkinsonism linked to chromosome 17, Niemann-Pick disease type C, neurofibromatosis type 1, neurofibromatosis type 2, megalencephalic leukoencephalopathy with subcortical cysts type 1, Pelizaeus-Merzbacher disease, Pompe disease, myotonic dystrophy type 2 (DM2), and myotonic dystrophy type 1 (DM1).
